Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.</li>
<li>There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.</li>
<li>The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. </li>
</ul>


1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.
There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.
The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. 


<ul>
<li>The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.</li>
<li>Group revenue is expected to have increased by 13% or 15% on a constant currency basis, to approximately £30.4m, reflecting upsell of the latest iterations of its Decision Intelligence software and the successful go live with several major new customers.</li>
<li>SaaS revenues increased by approximately 13%, or 14% on a constant currency basis, up from 8% growth in the prior year. </li>
</ul>


The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.
Group revenue is expected to have increased by 13% or 15% on a constant currency basis, to approximately £30.4m, reflecting upsell of the latest iterations of its Decision Intelligence software and the successful go live with several major new customers.
SaaS revenues increased by approximately 13%, or 14% on a constant currency basis, up from 8% growth in the prior year. 


<ul>
<li>The developer of international green fertiliser projects today announced the signing of non-binding Heads of Terms with Hy24's managed Clean H2 Infra Fund for an up to US$115m investment in the Villeta project in Paraguay.</li>
<li>Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes p.a. green fertiliser project.</li>
<li>The agreement marks a significant milestone towards Final Investment Decision. </li>
</ul>


The developer of international green fertiliser projects today announced the signing of non-binding Heads of Terms with Hy24's managed Clean H2 Infra Fund for an up to US$115m investment in the Villeta project in Paraguay.
Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes p.a. green fertiliser project.
The agreement marks a significant milestone towards Final Investment Decision. 


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

United Kingdom

Fusion Antibodies Ltd operates as a bio-technology company. The Company develops antibodies for therapeutic drug and diagnostic applications. Fusion Antibodies also renders antibody class switching, stable cell line development, mammalian transient and bacterial protein expression, custom monoclonal antibody production, and sequencing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Hybridan Small Cap Feast: 07/05/2025

1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.

Hybridan

Hybridan Small Cap Feast: 24/04/2025

The provider of Decision Intelligence software for service operations, provided an update on trading for the year ended 31 March 2025.

Hybridan

Hybridan Small Cap Feast: 27/02/2025

Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes...

Hybridan

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)